Results 41 to 50 of about 184,127 (310)

Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture [PDF]

, 2015
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established ...
Fraga-Silva, Rodrigo, Stergiopulos, Nikolaos, Trachet, Bram   +2 more
core   +2 more sources

Biophysical analysis of angiotensin II and amyloid‐β cross‐interaction in aggregation and membrane disruption

FEBS Letters, EarlyView.
Angiotensin II (AngII), a neuropeptide, interacts with amyloid‐β (Aβ), a key player in Alzheimer's disease. This study reveals that AngII reduces Aβ aggregation and membrane disruption in vitro. Biophysical assays and molecular modeling suggest AngII binds disordered Aβ forms, potentially modulating early amyloidogenic events and contributing to ...
Mohsen Habibnia, Eric Catalina‐Hernandez, Maialen Cabrerizo‐Idiazabal, Ramon Barnadas‐Rodríguez, Mario Lopez‐Martin, Alex Peralvarez‐Marin   +5 more
wiley   +1 more source

ACE-I induced angioedema: a case report and review of literature [PDF]

, 2009
Although rare, angioedema has been documented to occur following the administration of angiotensin-Converting Enzyme Inhibitors. Angiotensin-converting enzyme inhibitors are the leading cause of drug induced angioedema.
Adebayo, Philip Babatunde, Alebiosu, Olutayo Christopher   +1 more
core   +3 more sources

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

THE EFFICACY OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANTAGONISTS OF THE RECEPTORS OF THE 1ST TYPE OF ANGIOTENSIN II IN PATIENTS WITH CORONARY ARTERY DISEASE POSTINFARCTION CARDIOSCLEROSIS COMBINED WITH DIABETES MELLITUS TYPE 2 AND ARTERIAL HYPERTENSION

В мире научных открытий, 2016
The article discusses the effectiveness of 3-month therapy with angiotensin converting enzyme inhibitors fosinopril receptor and antagonists of the angiotensin II valsartan to achieve target BP(
Zarina Vyacheslavovna Bitarovа, Oleg Valeryevich Remizov, Zamira Tatarbekovna Astakhova, Zalina Aslanbekovna Toguzova   +3 more
doaj   +1 more source

Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Pediatric Patients with Mid to Severe Aortic Valve Regurgitation [PDF]

, 2018
The long-term benefit of angiotensin-converting enzyme inhibitors in pediatric patients with aortic valve regurgitation is under consideration.
Bauersfeld, Urs, Gisler, Fabian, Harpes, Paul, Knirsch, Walter   +3 more
core  

The role of fibroblast growth factors in cell and cancer metabolism

FEBS Letters, EarlyView.
Fibroblast growth factor (FGF) signaling regulates crucial signaling cascades that promote cell proliferation, survival, and metabolism. Therefore, FGFs and their receptors are often dysregulated in human diseases, including cancer, to sustain proliferation and rewire metabolism.
Jessica Price, Chiara Francavilla
wiley   +1 more source

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. [PDF]

, 2018
Background Our objective was to determine patterns of antihypertensive agent use by stage of chronic kidney disease (CKD) and to evaluate the association between different classes of antihypertensive agents with nonrenal outcomes, especially in advanced ...
Johansen, Kirsten L, Ku, Elaine, Lin, Feng, McCulloch, Charles E, Vittinghoff, Eric   +4 more
core  

Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2 [PDF]

, 2009
Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in the therapeutic benefit for ACE2 overexpression in the heart.
Allen, James M., Baker, Andrew H., Chamberlain, Jeffrey S., Craig, Margaret Anne, Dominiczak, Anna F., Gilday, Kirsten, Graham, Delyth, Gregorevic, Paul, Masson, Rachel, McBride, Martin, Napoli, Claudio, Nicklin, Stuart A., Smith, Godfrey   +12 more
core   +1 more source

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study. [PDF]

Ren Fail
Kang SH, Kim GO, Kim BY, Son EJ, Do JY.
europepmc   +2 more sources